Clinical Information Provided by Beta-Hydroxybutyrate Measurement
Beta-hydroxybutyrate (BHB) measurement provides critical diagnostic and monitoring information for diabetic ketoacidosis (DKA), is superior to urine ketone testing, and should be the preferred method for both diagnosis and treatment monitoring of ketotic states.
Primary Clinical Applications
Diagnosis and Monitoring of DKA
BHB is the gold standard for diagnosing DKA and should be specifically measured rather than relying on general ketone tests. 1 The key diagnostic threshold is:
- Normal: <0.5 mmol/L
- Elevated/concerning: >0.5 mmol/L
- DKA diagnosis: Typically elevated alongside hyperglycemia and metabolic acidosis with increased anion gap 1
BHB is the predominant ketone body in DKA (typically present in equimolar amounts with acetoacetate normally, but shifts heavily toward BHB during ketotic states). 1 This is critical because traditional nitroprusside-based ketone tests do NOT measure BHB and will underestimate total ketone body concentration, potentially providing misleading clinical information. 1
Superiority Over Urine Ketone Testing
Blood BHB testing demonstrates clear clinical advantages over urine ketones:
- Children with type 1 diabetes using blood ketone testing had almost half the number of emergency department visits or hospitalizations compared to those using urine ketone testing 1
- Patients and caregivers were more likely to actually perform testing when using blood BHB meters 1
- Urine ketones have high sensitivity for ruling out DKA (high negative predictive value) but are inferior for diagnosis and monitoring 1
Specific Clinical Scenarios Requiring BHB Monitoring
High-Risk Populations
Individuals who should measure BHB when symptomatic include: 1, 2
- Type 1 diabetes patients
- Anyone with history of DKA
- Patients treated with SGLT2 inhibitors (both type 1 and type 2 diabetes)
Trigger symptoms for testing:
- Unexplained hyperglycemia
- Abdominal pain
- Nausea
- Any signs of illness
Critical Monitoring Pitfall
Never use nitroprusside-based blood ketone tests to monitor DKA treatment. 1 During successful DKA therapy, BHB falls while acetoacetate and acetone may paradoxically increase, making nitroprusside tests misleading and potentially dangerous for treatment decisions. 1
Additional Clinical Contexts
Non-Diabetic Ketotic States
BHB elevation occurs in multiple conditions beyond DKA: 1
- Alcoholic ketoacidosis (positive ketones WITHOUT hyperglycemia)
- Pregnancy (up to 30% of first morning specimens in pregnant women)
- Starvation states
- Post-hypoglycemia
- Ketogenic diets (intentional nutritional ketosis)
Emerging Applications
Recent evidence suggests BHB has utility in:
- Insulinoma diagnosis: All insulinoma cases developed hypoglycemia within 43 hours with BHB ≤1.2 mmol/L; adding BHB >2.7 mmol/L as a stopping criterion for 72-hour fasts reduced hospitalization time without missing cases 3
- Pediatric emergency diagnosis: BHB of 5.3 mmol/L predicted DKA with 90.6% accuracy, 76.7% sensitivity, and 96.4% specificity 4
Practical Implementation
Specimen Requirements
- Blood samples: heparin, EDTA, fluoride, citrate, or oxalate 1
- Whole blood stable at 4°C for 24 hours
- Serum/plasma stable 1 week at room temperature, 2 weeks at 4°C 1
Correlation with Other Markers
BHB correlates well with:
- pH (r = -0.56, P<0.0001) 5
- Bicarbonate (r = -0.24, P=0.0161) 5
- BHB normalizes earlier than ketonuria in all cases 5
Treatment Monitoring
Resolution of acidosis or reduction in blood BHB is the traditional marker for successful DKA treatment, not serial nitroprusside-based ketone measurements. 1
Key Clinical Caveat
Approximately 24% of contemporaneously ordered BHB and urine ketone results are discordant, with the majority showing elevated BHB but normal urine ketones. 6 Kidney function appears to be a driving factor in these discrepancies, making BHB particularly important in patients with renal impairment.